Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.

BHV, manufacturer of hardware, firmware, desktop and cloud solutions and provider of turnkey engineering services, is presenting a technology preview of its new 4K 60 video processor platform at ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There are several more clinical candidates spanning several indications including BHV-8000, BHV-1300, BHV-1310, BHV-1400, BHV-1600, BHV-1510, BHV-1530, BHV-1500. However, all of these candidates ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

The latest BHV Bremische Hafen und Logistikvertretung's project logistics monitor shows a cautious outlook for the sector in ...

CALC is the principal failure mode of BHV fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Covalent binding of APD to residual glutaraldehyde in pericardial ...